To the Editor In their Viewpoint on preclinical Alzheimer disease (AD), Langa and Burke1 cite data from the Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) study2 to support the claim that positive results on amyloid positron emission tomography (PET) scans may lead to inappropriate use of AD medications in cognitively unimpaired individuals. Following published appropriate use criteria for amyloid PET,3 patients enrolled in the IDEAS study2 were required to meet clinical criteria for mild cognitive impairment (MCI) or dementia, and individuals with unimpaired cognition were excluded from the study. Physician choices about the treatment of patients with cognitive impairment in the IDEAS study2 should not be used to draw inferences regarding potential treatment of cognitively unimpaired individuals.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Rabinovici GD, Carrillo MC. Biomarker-Informed Treatment Decisions in Cognitively Impaired Patients Do Not Apply to Preclinical Alzheimer Disease. JAMA Intern Med. 2019;179(12):1736–1737. doi:10.1001/jamainternmed.2019.5114
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: